Qualigen Therapeutics Announces First Patient Dosed In The Phase 1a Clinical Trial Of QN-302 For Treatment Of Advanced Or Metastatic Solid Tumors
Qualigen Therapeutics Announces First Patient Dosed In The Phase 1a Clinical Trial Of QN-302 For Treatment Of Advanced Or Metastatic Solid Tumors
Qualigen Therapeutics 宣佈在用於治療晚期或轉移性實體瘤的 QN-302 的 1a 期臨床試驗中首位患者給藥
Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announces today that the first patient in the Phase 1a clinical trial has been dosed with QN-302, a potential first-in-class, investigational G-Quadruplex (G4)-selective transcription inhibitor designed for the treatment of advanced or metastatic solid tumors. The first clinical site is located at START Midwest in Grand Rapids, Michigan.
Qualigen Therapeutics, Inc.（納斯達克股票代碼：QLGN）是一家臨床階段的治療公司，專注於開發有可能被指定爲孤兒藥的成人和兒科癌症的治療方法。該公司今天宣佈，1a期臨床試驗的首位患者已經服用了 QN-302，這是一種潛在的同類首創、正在研究的G-四聯體（G4）選擇性轉錄抑制劑，專爲治療晚期或轉移性實體瘤而設計。第一個臨床中心位於密歇根州大瀑布城的START Midwest。
QN-302 works by selectively stabilizing G4 complexes prevalent in the promoter region of oncogenes in many tumor types, impeding transcription of G4-containing cancer genes, and may...
QN-302 的工作原理是選擇性地穩定許多腫瘤類型...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。